[ad_1] CHICAGO – Treatment with Sodium Glucose Cotransporter-2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim / Lilly) is associated with beneficial effects on the left ventricular (LV) structure and function in patients with …
Read More »Empagliflozin May Reduce Mass LV in Patients With CVD, Diabetes
